schliessen

Filtern

 

Bibliotheken

Trade, TRIPS, and pharmaceuticals

Summary The World Trade Organization's Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) set global minimum standards for the protection of intellectual property, substantially increasing and expanding intellectual-property rights, and generated clear gains for the pharmaceu... Full description

Journal Title: The Lancet (British edition) 2009, Vol.373 (9664), p.684-691
Main Author: Smith, Richard D, Prof
Other Authors: Correa, Carlos, Prof , Oh, Cecilia, PhD
Format: Electronic Article Electronic Article
Language: English
Subjects:
Quelle: Alma/SFX Local Collection
Publisher: Kidlington: Elsevier Ltd
ID: ISSN: 0140-6736
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_miscellaneous_66953764
title: Trade, TRIPS, and pharmaceuticals
format: Article
creator:
  • Smith, Richard D, Prof
  • Correa, Carlos, Prof
  • Oh, Cecilia, PhD
subjects:
  • Abridged Index Medicus
  • Analysis
  • Biological and medical sciences
  • Commerce - economics
  • Commerce - standards
  • Commerce - statistics & numerical data
  • Developing Countries
  • Drug Industry - economics
  • Drug Industry - statistics & numerical data
  • Drug Industry - trends
  • General aspects
  • Humans
  • Intellectual Property
  • Intellectual property law
  • Internal Medicine
  • International Cooperation
  • International trade
  • Interpretation and construction
  • Laws, regulations and rules
  • Malaysia
  • Medical sciences
  • Pharmaceutical industry
  • Pharmaceutical Preparations - economics
  • Pharmaceutical Preparations - standards
  • Pharmaceutical Preparations - supply & distribution
  • World Health Organization
ispartof: The Lancet (British edition), 2009, Vol.373 (9664), p.684-691
description: Summary The World Trade Organization's Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) set global minimum standards for the protection of intellectual property, substantially increasing and expanding intellectual-property rights, and generated clear gains for the pharmaceutical industry and the developed world. The question of whether TRIPS generates gains for developing countries, in the form of increased exports, is addressed in this paper through consideration of the importance of pharmaceuticals in health-care trade, outlining the essential requirements, implications, and issues related to TRIPS, and TRIPS-plus, in which increased restrictions are imposed as part of bilateral free-trade agreements. TRIPS has not generated substantial gains for developing countries, but has further increased pharmaceutical trade in developed countries. The unequal trade between developed and developing countries (ie, exporting and importing high-value patented drugs, respectively) raises the issue of access to medicines, which is exacerbated by TRIPS-plus provisions, although many countries have not even enacted provision for TRIPS flexibilities. Therefore this paper focuses on options that are available to the health community for negotiation to their advantage under TRIPS, and within the presence of TRIPS-plus.
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 0140-6736
fulltext: fulltext
issn:
  • 0140-6736
  • 1474-547X
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.5367043
LOCALfalse
PrimoNMBib
record
control
sourceidgale_proqu
recordidTN_cdi_proquest_miscellaneous_66953764
sourceformatXML
sourcesystemPC
galeidA241655239
sourcerecordidA241655239
originalsourceidFETCH-LOGICAL-15176-89ba426b2e198352b0334647f9f189437a81b89a952b74c8f584be24eb28b8d73
addsrcrecordideNqFkm9rFDEQxoMo9qx-BOV8UVG4rZlNNskiKKX4p1BQ7Am-C9ns7F3qbvZMdoV-e7N3R6v3pgQykPzmYWaeIeQ50FOgIN5eUeA0E5KJ11S9ESBlmcEDMgMueVZw-fMhmd0iR-RJjNeUUi5o8ZgcQQlC0oLPyMtlMDUu5svvF9-uFnPj6_lmbUJnLI6Ds6aNT8mjJgV8to_H5Menj8vzL9nl188X52eXGRQgRabKyvBcVDlCqViRV5QxLrhsygZUyZk0CipVmjJ9SW5VUyheYc6xylWlasmOyaud7ib0v0eMg-5ctNi2xmM_Ri1EWTApeAJPd-DKtKidb_ohGJtOjZ2zvcfGpfeznIMoipyVd8rbhDWadljHvk399T7-Dy7-AasxOo8xXdGt1kNcmTEe4MUOt6GPMWCjN8F1JtxooHoySW9N0pMDmiq9NUlDynux73SsOqzvsvauJOBkD5iYLGiC8dbFWy4HYIzyaWTvDgqwbjBTW2kirr23jA-7bEyu_nEYdLQOvcXaBbSDrnt3r8L7AwXbOj9tzS-8wXjdj8GnldGgY67pTmTSoGqrAOwv_mnP5w
sourcetypeAggregation Database
isCDItrue
recordtypearticle
pqid66953764
display
typearticle
titleTrade, TRIPS, and pharmaceuticals
sourceAlma/SFX Local Collection
creatorSmith, Richard D, Prof ; Correa, Carlos, Prof ; Oh, Cecilia, PhD
creatorcontribSmith, Richard D, Prof ; Correa, Carlos, Prof ; Oh, Cecilia, PhD
descriptionSummary The World Trade Organization's Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) set global minimum standards for the protection of intellectual property, substantially increasing and expanding intellectual-property rights, and generated clear gains for the pharmaceutical industry and the developed world. The question of whether TRIPS generates gains for developing countries, in the form of increased exports, is addressed in this paper through consideration of the importance of pharmaceuticals in health-care trade, outlining the essential requirements, implications, and issues related to TRIPS, and TRIPS-plus, in which increased restrictions are imposed as part of bilateral free-trade agreements. TRIPS has not generated substantial gains for developing countries, but has further increased pharmaceutical trade in developed countries. The unequal trade between developed and developing countries (ie, exporting and importing high-value patented drugs, respectively) raises the issue of access to medicines, which is exacerbated by TRIPS-plus provisions, although many countries have not even enacted provision for TRIPS flexibilities. Therefore this paper focuses on options that are available to the health community for negotiation to their advantage under TRIPS, and within the presence of TRIPS-plus.
identifier
0ISSN: 0140-6736
1EISSN: 1474-547X
2DOI: 10.1016/S0140-6736(08)61779-1
3PMID: 19167054
4CODEN: LANCAO
languageeng
publisherKidlington: Elsevier Ltd
subjectAbridged Index Medicus ; Analysis ; Biological and medical sciences ; Commerce - economics ; Commerce - standards ; Commerce - statistics & numerical data ; Developing Countries ; Drug Industry - economics ; Drug Industry - statistics & numerical data ; Drug Industry - trends ; General aspects ; Humans ; Intellectual Property ; Intellectual property law ; Internal Medicine ; International Cooperation ; International trade ; Interpretation and construction ; Laws, regulations and rules ; Malaysia ; Medical sciences ; Pharmaceutical industry ; Pharmaceutical Preparations - economics ; Pharmaceutical Preparations - standards ; Pharmaceutical Preparations - supply & distribution ; World Health Organization
ispartofThe Lancet (British edition), 2009, Vol.373 (9664), p.684-691
rights
0Elsevier Ltd
12009 Elsevier Ltd
22009 INIST-CNRS
3COPYRIGHT 2009 Elsevier B.V.
lds50peer_reviewed
citedbyFETCH-LOGICAL-15176-89ba426b2e198352b0334647f9f189437a81b89a952b74c8f584be24eb28b8d73
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
backlink
0$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21133047$$DView record in Pascal Francis
1$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19167054$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Smith, Richard D, Prof
1Correa, Carlos, Prof
2Oh, Cecilia, PhD
title
0Trade, TRIPS, and pharmaceuticals
1The Lancet (British edition)
addtitleLancet
descriptionSummary The World Trade Organization's Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) set global minimum standards for the protection of intellectual property, substantially increasing and expanding intellectual-property rights, and generated clear gains for the pharmaceutical industry and the developed world. The question of whether TRIPS generates gains for developing countries, in the form of increased exports, is addressed in this paper through consideration of the importance of pharmaceuticals in health-care trade, outlining the essential requirements, implications, and issues related to TRIPS, and TRIPS-plus, in which increased restrictions are imposed as part of bilateral free-trade agreements. TRIPS has not generated substantial gains for developing countries, but has further increased pharmaceutical trade in developed countries. The unequal trade between developed and developing countries (ie, exporting and importing high-value patented drugs, respectively) raises the issue of access to medicines, which is exacerbated by TRIPS-plus provisions, although many countries have not even enacted provision for TRIPS flexibilities. Therefore this paper focuses on options that are available to the health community for negotiation to their advantage under TRIPS, and within the presence of TRIPS-plus.
subject
0Abridged Index Medicus
1Analysis
2Biological and medical sciences
3Commerce - economics
4Commerce - standards
5Commerce - statistics & numerical data
6Developing Countries
7Drug Industry - economics
8Drug Industry - statistics & numerical data
9Drug Industry - trends
10General aspects
11Humans
12Intellectual Property
13Intellectual property law
14Internal Medicine
15International Cooperation
16International trade
17Interpretation and construction
18Laws, regulations and rules
19Malaysia
20Medical sciences
21Pharmaceutical industry
22Pharmaceutical Preparations - economics
23Pharmaceutical Preparations - standards
24Pharmaceutical Preparations - supply & distribution
25World Health Organization
issn
00140-6736
11474-547X
fulltexttrue
rsrctypearticle
creationdate2009
recordtypearticle
recordideNqFkm9rFDEQxoMo9qx-BOV8UVG4rZlNNskiKKX4p1BQ7Am-C9ns7F3qbvZMdoV-e7N3R6v3pgQykPzmYWaeIeQ50FOgIN5eUeA0E5KJ11S9ESBlmcEDMgMueVZw-fMhmd0iR-RJjNeUUi5o8ZgcQQlC0oLPyMtlMDUu5svvF9-uFnPj6_lmbUJnLI6Ds6aNT8mjJgV8to_H5Menj8vzL9nl188X52eXGRQgRabKyvBcVDlCqViRV5QxLrhsygZUyZk0CipVmjJ9SW5VUyheYc6xylWlasmOyaud7ib0v0eMg-5ctNi2xmM_Ri1EWTApeAJPd-DKtKidb_ohGJtOjZ2zvcfGpfeznIMoipyVd8rbhDWadljHvk399T7-Dy7-AasxOo8xXdGt1kNcmTEe4MUOt6GPMWCjN8F1JtxooHoySW9N0pMDmiq9NUlDynux73SsOqzvsvauJOBkD5iYLGiC8dbFWy4HYIzyaWTvDgqwbjBTW2kirr23jA-7bEyu_nEYdLQOvcXaBbSDrnt3r8L7AwXbOj9tzS-8wXjdj8GnldGgY67pTmTSoGqrAOwv_mnP5w
startdate2009
enddate2009
creator
0Smith, Richard D, Prof
1Correa, Carlos, Prof
2Oh, Cecilia, PhD
general
0Elsevier Ltd
1Elsevier
2Elsevier B.V
scope
0IQODW
1CGR
2CUY
3CVF
4ECM
5EIF
6NPM
7AAYXX
8CITATION
9BSHEE
107X8
sort
creationdate2009
titleTrade, TRIPS, and pharmaceuticals
authorSmith, Richard D, Prof ; Correa, Carlos, Prof ; Oh, Cecilia, PhD
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-15176-89ba426b2e198352b0334647f9f189437a81b89a952b74c8f584be24eb28b8d73
rsrctypearticles
prefilterarticles
languageeng
creationdate2009
topic
0Abridged Index Medicus
1Analysis
2Biological and medical sciences
3Commerce - economics
4Commerce - standards
5Commerce - statistics & numerical data
6Developing Countries
7Drug Industry - economics
8Drug Industry - statistics & numerical data
9Drug Industry - trends
10General aspects
11Humans
12Intellectual Property
13Intellectual property law
14Internal Medicine
15International Cooperation
16International trade
17Interpretation and construction
18Laws, regulations and rules
19Malaysia
20Medical sciences
21Pharmaceutical industry
22Pharmaceutical Preparations - economics
23Pharmaceutical Preparations - standards
24Pharmaceutical Preparations - supply & distribution
25World Health Organization
toplevel
0peer_reviewed
1online_resources
creatorcontrib
0Smith, Richard D, Prof
1Correa, Carlos, Prof
2Oh, Cecilia, PhD
collection
0Pascal-Francis
1Medline
2MEDLINE
3MEDLINE (Ovid)
4MEDLINE
5MEDLINE
6PubMed
7CrossRef
8Academic OneFile (A&I only)
9MEDLINE - Academic
jtitleThe Lancet (British edition)
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Smith, Richard D, Prof
1Correa, Carlos, Prof
2Oh, Cecilia, PhD
formatjournal
genrearticle
ristypeJOUR
atitleTrade, TRIPS, and pharmaceuticals
jtitleThe Lancet (British edition)
addtitleLancet
date2009
risdate2009
volume373
issue9664
spage684
epage691
pages684-691
issn0140-6736
eissn1474-547X
codenLANCAO
abstractSummary The World Trade Organization's Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) set global minimum standards for the protection of intellectual property, substantially increasing and expanding intellectual-property rights, and generated clear gains for the pharmaceutical industry and the developed world. The question of whether TRIPS generates gains for developing countries, in the form of increased exports, is addressed in this paper through consideration of the importance of pharmaceuticals in health-care trade, outlining the essential requirements, implications, and issues related to TRIPS, and TRIPS-plus, in which increased restrictions are imposed as part of bilateral free-trade agreements. TRIPS has not generated substantial gains for developing countries, but has further increased pharmaceutical trade in developed countries. The unequal trade between developed and developing countries (ie, exporting and importing high-value patented drugs, respectively) raises the issue of access to medicines, which is exacerbated by TRIPS-plus provisions, although many countries have not even enacted provision for TRIPS flexibilities. Therefore this paper focuses on options that are available to the health community for negotiation to their advantage under TRIPS, and within the presence of TRIPS-plus.
copKidlington
pubElsevier Ltd
pmid19167054
doi10.1016/S0140-6736(08)61779-1